Kineta Inc. (KA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for KA in the last 30 days. The most recent was published Oct 8, 2024.
Latest news
25 items- PRKineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid TumorsKineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The company will present additional scientific data in 2024 at an upcoming scientific meeting. SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed the enrollment of new patients into the monotherapy arm of the VI
- PRKineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, has announced that on November 8, 2024 Jason Henry M.D., Associate Director, Drug Development at Sarah Cannon Research Institute, Denver Colorado will be presenting the poster wi
- SECKineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- PRKineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer SEATTLE, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that TuHURA Biosciences Inc (TuHURA) is exercising its right to extend their exclusivity and right of first offer agreement (the "Agreement") for Kineta's VISTA blocking antibody KVA12123. Under the terms of the A
- SECKineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- PRKineta, Inc Transitioning from Nasdaq to OTC MarketsKineta will be trading under the symbol "KANT" on OTC Pink Kineta will continue to pursue strategic alternatives as previously announced TuHURA Biosciences has an exclusivity right and a right of first offer for Kineta's KVA12123 program The ongoing KVA12123 Phase 1 study is open for new patient enrollment and following those patients previously enrolled. SEATTLE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has transitioned from Nasdaq to the OTC Market. Kineta stock now trades under the ticker symbol "KANT" on the O
- SECKineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - KINETA, INC./DE (0001445283) (Filer)
- SECKineta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - KINETA, INC./DE (0001445283) (Filer)
- INSIDERSEC Form 4 filed by Director Foote Marion R4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERSEC Form 4 filed by Director Iadonato Shawn4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERSEC Form 4 filed by Director Peters Richard4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERSEC Form 4 filed by Director Drapkin Kimberlee C4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERSEC Form 4 filed by Director Dylla Scott J.4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERSEC Form 4 filed by Director Bartoszek Raymond J.4 - KINETA, INC./DE (0001445283) (Issuer)
- INSIDERSEC Form 4 filed by Director Arkowitz David4 - KINETA, INC./DE (0001445283) (Issuer)
- SECKineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- PRTuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab) Kineta anticipates the trial to be fully enrolled by the end of 2024 TAMPA, Fla. & SAN DIEGO, August 19, 2024 /PRNewswire/ -- TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Kinet
- PRKineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerEffective immediately, clinical sites in the VISTA-101 Phase 1/ Phase 2 clinical trial can resume screening of patients for enrollment in the clinical study 30 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) Kineta anticipates the trial to be fully enrolled by the end of 2024 SEATTLE, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that enrollment has res
- SECSEC Form 10-Q filed by Kineta Inc.10-Q - KINETA, INC./DE (0001445283) (Filer)
- NEWSKineta shares are trading higher after the company announced that it entered into an exclusivity and right of first offer agreement with TuHURA Biosciences to grant the immune-oncology company exclusive rights to acquire its Anti-VISTA antibody.
- NEWSTuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA AntibodyKVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined Concurrent $5 million investment from existing TuHURA shareholder preserves
- SECKineta Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - KINETA, INC./DE (0001445283) (Filer)
- PRTuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorKVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined Concurrent $5 million investment from existing TuHURA shareholder preserves TuHU
- PRKineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA BiosciencesTuHURA has an exclusive right to negotiate to acquire Kineta's KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a Phase 1/Phase 2 Clinical Study in the United States SEATTLE, July 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into an exclusivity and right of first offer agreement (the "Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to
- SECKineta Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - KINETA, INC./DE (0001445283) (Filer)
KA FAQ
6 questionsWhat is the latest news on KA?
Quantisnow has not tracked any new filings, ratings or press releases for KA in the last 30 days. The most recent wire item was published on October 8, 2024.Where does KA stock trade?
Kineta Inc. (KA) is listed on NASDAQ.What sector and industry is KA in?
Kineta Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Kineta Inc. go public?
Kineta Inc. (KA) completed its IPO in 2016.What companies are similar to KA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare KA side-by-side with any of them on Quantisnow.How can I track KA on Quantisnow?
Quantisnow aggregates Kineta Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KA to receive live email and push alerts on every new disclosure.